• 429
  • 0

Late Breaking research from Frykberg, Peters et al,  at the 2018 ADA. Exciting stuff from a group of the best wounds docs in the world. Enjoy. PVM

Multinational, Multicenter, Prospective, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy of Cyclical Topical Wound Oxygen Therapy (TWO2) in the Treatment of Chronic Diabetic Foot Ulcers

ROBERT FRYKBERG, PETER J. FRANKS, MICHAEL E. EDMONDS, JONATHAN N. BRANTLEY, LUC TÉOT, THOMAS WILD, MATTHEW G. GAROUFALIS, ALIZA M. LEE, JANETTE THOMPSON, GERARD REACH, CYAANDI R. DOVE, KARIM LACHGAR and DIRK GROTEMEYER

Diabetes 2018 Jul; 67(Supplement 1): – https://doi.org/10.2337/db18-43-LB

Non-healing DFUs lead to increased mortality, morbidity and health economic burden. Our RCT (NCT02326337) was undertaken to explore the efficacy of Topical Wound Oxygen (TWO2) homecare therapy in healing DFUs that had failed to heal with Standard of Care (SOC) alone. A Group Sequential Design was utilized with 2 interim analyses, requiring a significance of p<0.022 at each. All subjects meeting the incl/excl criteria were enrolled into a run-in of SOC that included gold-standard offloading and sharp debridement. Only DFUs not on a proven healing trajectory with SOC alone (<30% wound area reduction) were randomized into the active phase of the study, where they were assigned (double blind) to either active, or sham (placebo), TWO2 device treatment arms. The primary endpoint of the study was ulcers healed at 12 weeks. At the first interim analysis point of 73 subjects, the active TWO2 arm was shown to be significantly superior to the sham arm (Pearson Chi2 =7.2707, P=0.007). Multivariable analysis using logistic regression and Cox proportional hazards modelling of the secondary outcome measure of time to heal showed no other covariates achieved significance. The active TWO2 arm showed nearly 4 times the likelihood to heal DFUs in 12 weeks compared to the sham arm HR 3.88 (95% CI 1.40 to 10.71), p=0.009. 

Read the rest at: https://diabetes.diabetesjournals.org/content/67/Supplement_1/43-LB

Comments

comments

Author

PV Mayer

Dr. Perry Mayer is the Medical Director of The Mayer Institute (TMI), a center of excellence in the treatment of the diabetic foot. He received his undergraduate degree from Queen’s University, Kingston and medical degree from the Royal College of Surgeons in Ireland.

Add Comment